Today marks a significant milestone for us at Aizon, as we’re thrilled to announce the successful closure of $20 million in Series C funding. This round, spearheaded by NewVale Capital, a growth equity fund renowned for its investment in service businesses that excel in pharmaceuticals and biotechnology, signals a new chapter in our journey. We’re also proud to have the continued backing from our existing investors, including Atlantic Bridge, Crosslink Capital, and Uncork Capital. This substantial investment not only underlines our leadership in AI-enhanced pharmaceutical manufacturing but also gears us up for a phase of accelerated growth and innovation.
At Aizon, we’re passionate about transforming pharmaceutical manufacturing operations with our Artificial Intelligence (AI) SaaS solutions. Our platform leverages the most advanced predictive analytics, artificial intelligence, and smart factory technologies, making it the most powerful and accessible GMP AI platform for pharmaceutical manufacturers. This enables our customers to unlock groundbreaking insights, enhance decision-making, discover new optimization paths, reduce costs, anticipate deviations, and elevate their manufacturing systems. Quality and compliance are at the core of our mission; we adhere to GAMP5 guidelines for GMP processes, ensuring compliant data management across acquisition, storage, and consumption.
The fresh infusion of capital is a testament to the potential and success of our platform, fueling our ambition to execute our strategic roadmap more effectively. “This investment is a cornerstone for our company’s future growth. It not only validates the success of our platform but also equips us to better realize our strategic objectives,” says Pep Gubau, our CEO and co-founder. “Thanks to this additional funding and the unwavering support from our partners, we’re setting sights on fast-tracking the debut of our groundbreaking eBR solution in Q3 2024. This innovation will revolutionize the industry, reinforcing our dedication to constantly enhancing our offerings and empowering our clients with the most advanced technologies.”
Todd Holmes, managing partner at NewVale Capital, shares our enthusiasm: “We’re excited to contribute to this new chapter for Aizon, as it continues to redefine pharmaceutical manufacturing with its AI-driven solutions. Our investment focus is on companies like Aizon, which have a proven business model and offer significant value to their clients in the pharmaceutical space.”
About Us
Aizon is pioneering innovation in pharmaceutical manufacturing with our advanced, GMP-compliant predictive analytics platform. Our unique blend of industrialized AI and contextualized Historian data sets us apart, offering unmatched insights and improved decision-making in pharma manufacturing. To discover more about how we’re shaping the future, visit our website at http://www.aizon.ai.
About NewVale Capital
Established in 2022, NewVale Capital is a growth equity fund dedicated to fostering the next wave of Life Science services companies. The firm targets proven, revenue-generating service businesses across the Life Science ecosystem that play a crucial role in delivering medicines to patients. For more details, check out: http://www.newvalecapital.com.
